Ipsen announced results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS) will be presented as a late-breaking presentation… read more.
AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir), an oral… read more.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today… read more.
Pfizer announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi (marstacimab) to include patients 12 years of age and older weighing… read more.
Ipsen announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL)… read more.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment… read more.
Reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections, a new study has found. Thousands of… read more.
Genentech has received FDA approval of Ocrevus (ocrelizumab) intravenous (IV) infusion for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients 10 years of age and older who… read more.
Surgeons are an integral part of the health care system, supplying critical and urgent care in nearly every field of medicine. But surgeons are already in short supply,… read more.
Older people, care home residents and those living in poor-quality housing are facing growing danger from extreme heat, as new research warns that the UK is failing to… read more.
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
Advance directives document patient preferences for future care, including end-of-life. An analysis in the Journal of the American Geriatrics Society found that older patients with an advance directive that had… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
